Sep 07, 2022 7:00am EDT Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)
Sep 06, 2022 7:00am EDT Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
Aug 24, 2022 7:00am EDT Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology’s Kidney Week 2022
Aug 15, 2022 6:03pm EDT Unicycive Announces Second Quarter Financial Results and Provides Business Update
Jul 18, 2022 7:00am EDT Unicycive Announces Exclusive License and Development Agreement with Lee’s Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets
Jun 02, 2022 8:00am EDT Unicycive Initiates Pivotal Clinical Bioequivalence Study of Renazorb to Treat Hyperphosphatemia
May 12, 2022 7:00am EDT Unicycive Announces First Quarter Financial Results and Provides Business Update